Academic journal article Bulletin of the World Health Organization

GAVI Supports IPV Introduction for Polio

Academic journal article Bulletin of the World Health Organization

GAVI Supports IPV Introduction for Polio

Article excerpt

The GAVI Alliance has decided to support the introduction of inactivated polio vaccine (IPV) as part of routine immunization programmes in the world's 73 poorest countries.

The Polio Eradication and Endgame Strategic Plan 2013-2018, endorsed by the World Health Assembly last May, calls on countries to introduce at least one dose of IPV before the planned phased removal of oral polio vaccines, beginning with those manufactured with poliovirus type 2, as early as 2016.

Although there are three serotypes of the virus, the type 2 component in the trivalent oral polio vaccine (that targets all three virus types) is the one responsible for more than 80% of the cases of vaccine-derived polioviruses that have triggered outbreaks. That is why removing the type 2 component from the vaccine is vital to success.

Introducing IPV is an important part of the larger strategy to reduce the risks associated with the phased removal of all oral polio vaccines by improving overall immunity, continuing to provide immunity to type 2 and reducing the risk of new vaccine-derived outbreaks.

"The decision by GAVI to support the introduction of IPV in the world's poorest countries is absolutely critical to help secure a lasting polio-free world," said Dr Bruce Aylward, Assistant Director-General for Polio, Emergencies and Country Collaboration at the World Health Organization (WHO). …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.